Moderate to Severe Plaque Psoriasis Facts

  • Psoriasis is a chronic, immune-mediated disease, which is often characterized by thickened, well-demarcated, red plaques covered by white, silvery scales.1,2
    • Psoriasis affects ~7.5 million Americans.3,4
    • About 80 percent of those who have psoriasis have plaque psoriasis.5
    • Nearly 1.5 million US adults have cases that are considered moderate to severe.5,6
  • Plaque psoriasis can present at any age. Disease onset typically occurs either in early adulthood, with most patients experiencing symptoms before age 40, or at 50 to 60 years of age.7,8

Evaluation of Plaque Psoriasis Severity

In clinical practice, the physician generally makes a subjective, qualitative assessment of the severity of a patient's plaque psoriasis by combining the following observations/assessments10:

  • Body surface area (BSA) involvement
  • Symptoms
  • Location of psoriasis
  • Thickness of plaques
  • Presence or absence of psoriatic arthritis
  • Subjective assessment of the impact of the disease on the patient's life

Involvement of plaque psoriasis on the hands, feet, face, and genitals should be considered in evaluating the severity of disease.10

For information about the treatment guidelines from the American Academy of Dermatology, download the AAD guidelines now.

You will need Adobe Acrobat Reader to view certain documents on this page. If you do not already have it, download it for free from Adobe's website. Get Adobe® Reader®.


ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw 75% skin clearance in their moderate to severe plaque psoriasis in 3 months with ENBREL. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months. ENBREL can work fast; many patients saw improvement within 2 months. Your results may vary.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Over 172,000 ENBREL patients have joined the ENBREL Support™ program.
Our clinical experience

ENBREL has been prescribed by nearly 11,000 dermatology professionals in the U.S.9*

Learn more about our experience arrow

* Dermatologists, nurse practitioners, physician's assistants in dermatology offices, and dermatology subspecialists, which include D, DS, DMP, PDD, and some NP, PA, and IM/PCPs. Based on cumulative data from 2003 through May 2011.

Colleen noticed significant improvement within 8 to 10 weeks of starting ENBREL. She feels like she can manage her plaque psoriasis even though her skin is not completely cleared.

"I've had such a positive experience with ENBREL. It's great to be able to go around and wear a tank top."